Syneos Health Inc (SYNH) Stake Lessened by Morgan Stanley

Morgan Stanley lessened its stake in shares of Syneos Health Inc (NASDAQ:SYNH) by 12.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 161,559 shares of the company’s stock after selling 22,043 shares during the quarter. Morgan Stanley owned about 0.16% of Syneos Health worth $8,328,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SYNH. First Manhattan Co. bought a new stake in shares of Syneos Health during the 3rd quarter worth about $103,000. Campbell & CO Investment Adviser LLC bought a new stake in Syneos Health during the 3rd quarter valued at approximately $294,000. Cim Investment Mangement Inc. bought a new stake in Syneos Health during the 3rd quarter valued at approximately $297,000. Seven Eight Capital LP bought a new stake in Syneos Health during the 3rd quarter valued at approximately $327,000. Finally, BB&T Corp boosted its stake in Syneos Health by 26.7% during the 3rd quarter. BB&T Corp now owns 6,602 shares of the company’s stock valued at $341,000 after purchasing an additional 1,393 shares during the period.

Syneos Health stock opened at $52.66 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 0.97 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $5.23 billion, a price-to-earnings ratio of 27.14, a PEG ratio of 1.42 and a beta of 1.51. Syneos Health Inc has a 12 month low of $31.10 and a 12 month high of $53.95.

Several analysts recently weighed in on SYNH shares. William Blair upgraded Syneos Health from a “market perform” rating to an “outperform” rating in a research note on Friday, October 19th. ValuEngine upgraded Syneos Health from a “hold” rating to a “buy” rating in a research note on Saturday, November 10th. Zacks Investment Research downgraded Syneos Health from a “buy” rating to a “hold” rating in a research note on Saturday, November 17th. Finally, SunTrust Banks decreased their target price on Syneos Health to $55.00 and set a “buy” rating for the company in a research note on Wednesday, December 19th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Syneos Health currently has an average rating of “Buy” and an average price target of $53.44.

In other news, CFO Jason M. Meggs purchased 3,650 shares of the business’s stock in a transaction on Monday, December 17th. The stock was purchased at an average price of $41.25 per share, with a total value of $150,562.50. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Alistair Macdonald sold 6,697 shares of the company’s stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $53.04, for a total value of $355,208.88. The disclosure for this sale can be found here. Corporate insiders own 0.57% of the company’s stock.

WARNING: “Syneos Health Inc (SYNH) Stake Lessened by Morgan Stanley” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2019/02/13/syneos-health-inc-synh-stake-lessened-by-morgan-stanley.html.

About Syneos Health

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

See Also: Put Option

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit